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An increasing proportion of patients with advanced non-small cell lung cancer (NSCLC) are
over 70 years old, raising unique challenges for treatment decision-making. While these
patients are underrepresented in clinical trials, there is an emerging body of evidence
associated with this group. The lesson of comprehensive geriatric assessment is that
chronological age does not always correlate with physiological age and a variety of impor-
tant co-morbidities and geriatric syndromes can go undetected in a typical history and
physical. These co-morbidities and expected physiologic changes due to aging complicate
decision-making around appropriate treatment. This review discusses geriatric assess-
ment in elderly cancer patients and evaluates the current evidence for chemotherapy and
targeted therapy for patients with advanced NSCLC aged 70 years.≥
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INTRODUCTION
The number of seniors in Canada is projected to more than dou-
ble between 2005 and 2036 (1) and global life expectancy has
increased continuously over the last 40 years (2). Forty-three per-
cent of cancers in 2010 were diagnosed in patients 70 years or older
(3). Therefore, barring a significant change in cancer incidence,
the absolute number of cancers diagnosed in elderly patients
can be expected to increase substantially both in Canada and
worldwide.
Worldwide, lung cancer is the leading cause of cancer-related
mortality and by 2010 was the fifth overall leading cause of death
(4, 5). Eighty-five percent of diagnosed lung cancer patients have
non-small cell lung cancer (NSCLC) (6, 7). The median age of
diagnosis is 70 years and has been increasing (7, 8). Lung cancer
is therefore a disease of older adults and up to 70% of patients
are diagnosed in advanced stage, where the standard treatment is
systemic therapy (8).
This advanced age is an important treatment consideration
due to the complex interplay of physiologic changes associated
with aging, co-morbidities, competing mortality, and potential
differences in priorities among younger vs. older individuals when
prognosis is limited. These issues are compounded by difficulty in
predicting both benefit from chemotherapy and risk of toxicity
in older patients due to historical underrepresentation in clinical
trials (9, 10).
This narrative review will discuss the complexity of treating
geriatric patients and outline the current state of evidence for
the use of chemotherapy in this population for the treatment of
advanced lung cancer.
PHYSIOLOGIC CHANGES
Physiologic changes with aging occur in a number of organ systems
that can affect the safety of chemotherapy (Table 1). Glomerular
filtration rate is typically estimated to decrease by 1 mL/min/year
beyond age 40 (11–14). In addition to this reduction in renal
clearance, there is also impairment in the handling of water and
electrolytes (13, 15). These changes can increase the risk to elderly
lung cancer patients for toxicity from drugs primarily cleared by
the kidneys, as well as dehydration and electrolyte imbalances.
The gastrointestinal system also changes with age, affecting
drug absorption and the risk of mucositis (16, 17). Inconsistency
in absorption results from reduced gastric blood flow, delayed
gastric emptying, and a reduction in intestinal absorptive capacity
(18–21). The vulnerability to mucosal injury arises from alter-
ation of protective mechanisms, including a reduction in mucus
and bicarbonate secretion (18). More importantly, elderly indi-
viduals generally show a decrease in hepatic mass and blood flow,
which reduces drug metabolism (22). A reduction in activity of
the cytochrome P450 system can also occur, resulting in a higher
risk of drug interactions (23). The changes in metabolism can be
further exacerbated by body composition changes that increase
fat content and decrease water composition, thereby altering the
volume of distribution for many drugs (24).
Finally, important changes occur in the bone marrow, with
decreased cellularity, precursor proliferation, and cell mobilization
(25, 26). These changes result in decreased bone marrow reserve.
This altered bone marrow responsiveness increases the risk of mar-
row suppression and associated complications from chemotherapy
and can delay further treatment administration (27, 28).
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Table 1 | Physiologic changes with aging.
Organ system Changes Effect on chemotherapy
Renal Decreased glomerular filtration Decline in renal drug clearance that increases risk of drug toxicity
Impaired water and electrolyte handling Increased risk of dehydration
Gastrointestinal Decreased gastric blood flow and delayed gastric emptying Variable drug absorption
Decreased absorptive capacity Decreased absorption of oral drugs
Decreased mucosal repair Vulnerability to mucositis
Hepatobiliary Decreased liver mass and blood flow Reduced hepatic metabolism
Reduction in cytochrome P450 activity Greater vulnerability to P450 associated with drug interactions
Body composition Increased fat and decreased water Changes drug volume of distribution
Hematologic Decreased marrow cellularity, proliferation, and mobilization Impaired response to cytopenias, delayed blood count recovery,
and higher risk of infection
PREDICTION OF TOXICITY
These physiologic shifts can increase the risk of chemotherapy
toxicity in older individuals. However, clinical experience iden-
tifies many patients who seem much younger (or older) than
their chronological age. This heterogeneity was strikingly demon-
strated through comparison of life expectancies within geriatric
age groups. Life expectancy for a 75-year-old woman ranged from
6.8 years (lowest 25th percentile) to 17 years (highest 25th per-
centile) and the same values for a man are 4.9 and 14.2 years
(29). This variation in life expectancy reflects differences in base-
line health, comorbidity, and genetics (30). It seems reasonable
to hypothesize that the individual with better life expectancy has
less risk of toxicity and more chance of benefit from chemother-
apy, since they have less risk of competing causes of mortality. The
challenge is identifying these patients and improving the up to 44%
of lung cancer patients≥70 years, who may require hospitalization
during chemotherapy (31).
COMPREHENSIVE GERIATRIC ASSESSMENT
Historically, physicians used a combination of performance status
(PS), measured using the Eastern Cooperative Oncology Group
(ECOG) PS scale, and organ function as determined through
blood work to determine, which patients qualified for chemother-
apy treatment (32). This approach has been demonstrated to per-
form poorly when compared to more formal geriatric assessment
(33–35). Comprehensive geriatric assessment (CGA) is usually
composed of medical, functional, mental, social, and nutritional
assessments, as well as explicit assessment of prescription drug
use (36). A variety of studies have been completed to evaluate the
usefulness of CGA in oncology patients. Systematic reviews of the
available evidence show that CGA identifies problems that would
otherwise be missed, leads to modifications in treatment plans,
and helps predict toxicity from chemotherapy (37–42). Modifica-
tion of treatment plans occurs in 21–53% of patients, suggesting
that oncologists believe the additional information is valuable
(42). CGA is also better than physician opinion for identifying
frail elderly patients who experience greater toxicity (43). When
tested in elderly NSCLC patients, CGA was feasible (44–46). Frail
patients also exhibited poorer survival (46). However, when Corre
et al. allocated patients to treatment based on CGA, survival was
not different between groups, but toxicity was reduced in the arm
allocating treatment using CGA (47).
OTHER PREDICTIVE TOOLS
While a CGA can be very useful, it has not become a routine
part of oncologic care because it is time and labor intensive.
The mean duration of CGA during one prospective study was
80 min/patient (48). Such a time commitment is difficult to under-
take in lung cancer patients with metastatic disease, since it may
delay patient throughput in clinic and/or delay commencement
of treatment, a serious concern when patients have an average
life expectancy of 10–12 months (8). In light of these concerns,
a number of groups have attempted to shorten the CGA or pro-
vide a screening tool. Two groups have published new tools geared
toward predicting chemotherapy toxicity and derived from multi-
variable analyses of CGAs conducted in cancer patients (Table 2)
(33, 49). The chemotherapy risk assessment scale for high-age
patients (CRASH) is actually composed of two scores, one for
hematologic toxicity and another for non-hematologic toxicity
(49). Diastolic blood pressure, instrumental activities of daily liv-
ing (IADL), lactate dehydrogenase, and a proprietary Chemotox
score help stratify the likelihood of experiencing Grade 3–4 hema-
tologic toxicity into low (7%), medium-low (23%), medium-high
(54%), and high (100%). For non-hematologic adverse events,
the predictors are: ECOG PS, mini mental status, mini nutritional
assessment, and the Chemotox score. The same predictive cate-
gories for non-hematologic toxicity predict risks of 33, 46, 67, and
93% (49). The Chemotox score is a quantitation of the toxicity
of chemotherapy regimens that the group developed previously
(50, 51). The cohort used for the CRASH score contained 21%
lung cancer patients. The Cancer Aging Research Group (CARG)
derived another predictive tool (33, 52). The CARG score uses 11
factors to stratify risk: age ≥72, cancer type, standard chemother-
apy dosing, polychemotherapy, low hemoglobin, low creatinine
clearance, fair or worse hearing, falls, needing help with med-
ications, trouble walking 1 block, and decreased social activity.
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Table 2 | Significant factors in scores predicting chemotherapy toxicity.
CRASH score (49) Hematologic Non-hematologic
Diastolic blood pressure ECOG performance
status
IADL Mini mental status
LDH Mini nutritional
assessment
Chemotox score Chemotox score
CARG score (33) Predictive factors
Age ≥72 years
Standard chemotherapy dosing
Multi-drug chemotherapy
Low hemoglobin
Low creatinine clearance
Decreased hearing
Fall within 6 months
Needs help taking medications
Limited in walking 1 block
Decreased social activity
IADL, instrumental activities of daily living; LDH, lactate dehydrogenase; ECOG,
Eastern Cooperative Oncology Group.
This score classified lung cancer patients into low (10%), inter-
mediate (40%), or high (60%) risk of Grade 3–5 toxicity (52).
This score was better able to stratify risk of toxicity than Karnof-
sky PS alone. Both of these predictive tools are exciting because
they provide information that can be used to discuss chemother-
apy treatment with elderly patients. Unfortunately, neither has
been validated outside of the initial population and, therefore,
widespread adoption is not yet justified.
EVIDENCE FOR CHEMOTHERAPY
Since 1995, standard first line chemotherapy for younger patients
with stage IV NSCLC has been a platinum doublet. The
meta-analysis supporting this recommendation demonstrated a
10% improvement in 1-year survival for patients treated with
chemotherapy compared to supportive care (53). However, the
first randomized trial focusing specifically on elderly patients was
not published until 1999 (54, 55). Since then, only a few random-
ized trials have been conducted in patients 70 years and older with
metastatic NSCLC. Most recommendations have been based on
subgroup analyses or cohort studies. This lower level of evidence
has likely contributed to uncertainty among health professionals
regarding the standard of care in these patients.
The primary trial investigating the utility of single-agent
chemotherapy compared to the best supportive care in elderly
patients with metastatic NSCLC was the Elderly Lung Cancer
Vinorelbine Italian Study (ELVIS) (55). The experimental arm of
this RCT was single-agent vinorelbine (30 mg/m2) administered
on days 1 and 8 of a 21-day cycle. This treatment resulted in an
improvement in median survival (28 vs. 21 weeks) and 1-year sur-
vival (32 vs. 14%), in addition to improvement in some lung cancer
symptoms. Despite falling short of its 350 patient accrual target
and closing prematurely, this established a new standard of care,
which was incorporated as the control arm in further studies.
DOUBLET CHEMOTHERAPY
Subsequent trials have evaluated doublet chemotherapy regimens.
Due to concerns about toxicity, these trials initially examined
non-platinum chemotherapy combinations. The Southern Italy
Cooperative Oncology Group (SICOG) conducted an RCT com-
paring gemcitabine and vinorelbine in combination to vinorelbine
alone (56). The combination arm reported a median survival of
29 weeks compared to 18 weeks for vinorelbine alone. While this
difference was statistically significant, there were concerns that
the control group had worse survival than expected. These con-
cerns prompted the multicenter Italian lung cancer in the elderly
study (MILES),which compared three arms: vinorelbine plus gem-
citabine, gemcitabine alone, and vinorelbine alone (57). Whereas,
the SICOG trial enrolled 120 patients, MILES randomized 698
patients between the three arms. Median survivals were 30, 28, and
36 weeks for each of the arms, respectively. There was no statisti-
cally significant difference. There was, however, greater toxicity
in the combination arm, specifically for neutropenia, thrombo-
cytopenia, anemia, vomiting, constipation, and hepatic toxicity
(57). These results do not support the use of the combination of
vinorelbine and gemcitabine.
Further evaluation of doublet chemotherapy in patients
≥70 years was pursued. In one RCT of elderly patients or those
with ECOG PS 2, the combination of gemcitabine and pacli-
taxel improved median survival to 9.2 months compared with
5.1 months for gemcitabine alone (58). However, a RCT in
the same mixed population comparing gemcitabine/docetaxel to
weekly docetaxel reported no difference in survival (59). A system-
atic review with meta-analysis of RCTs comparing non-platinum
doublets with single-agent therapy for elderly patients showed no
survival advantage to doublet therapy and higher risk of throm-
bocytopenia (60). Perhaps the most promising regimen was the
combination of carboplatin with paclitaxel. One phase II trial
demonstrated that weekly paclitaxel combined with carboplatin
resulted in a 14-month median survival with quite manageable
toxicity (61). Interestingly, when compared to standard paclitaxel,
weekly paclitaxel appears to have equivalent benefit, but reduces
the risk of neutropenia and peripheral neuropathy (62). The land-
mark trial investigating the use of platinum doublets in the elderly
is Intergroupe Francophone Cancérologie Thoracique (IFCT)-
0501 (63). This trial included 451 patients aged 70–89 years, with
locally advanced or metastatic NSCLC and a PS of ECOG 0–2.
Patients were randomized to carboplatin and weekly paclitaxel vs.
monotherapy with either gemcitabine or vinorelbine. The trial was
stopped early after interim analysis demonstrated superiority for
the doublet regimen. Median overall survival was 10.3 months for
carboplatin and paclitaxel compared to 6.2 months for monother-
apy (hazard ratio 0.64, 95% CI 0.52–0.78, p< 0.0001). The largest
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increases in toxicity for doublet chemotherapy were neutropenia
(48.4 vs. 12.4%) and asthenia (10.3 vs. 5.8%) (63). Point esti-
mates were quite consistent for all subgroups and multivari-
able analysis confirmed expected prognostic factors like sex, PS,
adenocarcinoma histology, and smoking history.
One final trial, conducted in Japan by Takeda et al., has only
been published in abstract form (64). The trial enrolled 276
patients, who were chemotherapy naïve, age >70 years, ECOG
PS 0–1, and with stage III/IV NSCLC. Patients were randomized
to receive either docetaxel every 3 weeks or weekly cisplatin–
docetaxel. Enrollment was stopped early due to futility, with
median survival times of 13.3 months for cisplatin–docetaxel and
17.3 months for docetaxel alone (hazard ratio 1.557, 95% CI
0.976–2.485). Interestingly, neutropenia was far more common
with docetaxel alone than the doublet regimen 88 vs. 11%. The sur-
vival of the monotherapy group was remarkably high compared
previous trials (65–67).
The majority of subgroup analyses from earlier trials sug-
gest that survival is similar, though not always equal, between
younger and older patients with advanced NSCLC who receive
the same chemotherapy (68–71). The evidence suggests that the
results of IFCT-0501 should form the standard of care for first
line chemotherapy treatment in fit elderly patients with advanced
NSCLC, especially when no molecular abnormalities are detected.
In the second line setting, there are no elder-specific tri-
als. A retrospective analysis of the JMEI trial comparing doc-
etaxel to pemetrexed was completed for patients ≥70 years old
vs. younger patients. Median survival of 9.5 and 7.7 months was
reported for elderly patients receiving pemetrexed (n= 47) and
docetaxel (n= 39). In younger patients, these values were 7.8 and
8.0 months. Febrile neutropenia occurred in only 2.5% of elderly
patients receiving pemetrexed, but 19% of those being treated with
docetaxel (p= 0.025) (72).
TARGETED THERAPIES
BEVACIZUMAB
Bevacizumab is a monoclonal antibody that targets vascular
endothelial growth factor (VEGF) and can be used in combination
with first line platinum-based chemotherapy. Two trials, ECOG
4599 and AVAiL, originally tested the addition of bevacizumab to
standard chemotherapy (73, 74). Analyses of the elderly patients
in both of these trials were conducted. The AVAiL trial, comparing
cisplatin and gemcitabine with or without bevacizumab, showed
no improvement in overall survival in the elderly population
(n= 304), with the addition of bevacizumab (73). An analysis of
patients≥70 years in the ECOG 4599 trial of carboplatin and pacli-
taxel with or without bevacizumab reported overall survival was
11.3 months with bevacizumab and 12.1 months without. There
was a higher incidence of bleeding, neutropenia, and proteinuria
in older compared to younger patients (74). There does not appear
to be compelling evidence to include bevacizumab for those older
than 65–70 years of age.
EGFR TYROSINE KINASE INHIBITORS
Molecularly defined subtypes of NSCLC have become incredibly
important to management over the last 5 years. Epidermal growth
factor receptor (EGFR) mutations are detected in approximately
15% of Caucasian patients with advanced NSCLC and these
mutations are found more often, but not exclusively in younger,
never smoking women, or those of Asian ethnicity (75). The pres-
ence of an EGFR mutation is highly predictive of benefit from
EGFR tyrosine kinase inhibitors (TKIs) (76). More widespread
screening of all NSCLC tumor samples for molecular abnormali-
ties will increase the number of EGFR mutations identified in the
elderly. Available data demonstrate EGFR TKIs (erlotinib,gefitinib,
or afatinib) result in better progression free survival (PFS) and
favorable toxicity compared to chemotherapy in NSCLC patients
with an EGFR mutation (76–79). While few studies have examined
the effect of this strategy exclusively in elderly patients, available
data would suggest that elderly patients have similar response rate
and PFS (80–84). Toxicities reported were the expected diarrhea,
rash, and risk of transaminitis.
The NCIC BR.21 trial evaluated erlotinib in NSCLC patients
who progressed after one or two prior chemotherapy treatments
regardless of EGFR mutation status. The improvement in overall
survival was seen in both EGFR mutated and wild type patients. A
retrospective analysis of treatment effect and age in BR.21 found
no statistically significant difference in treatment effect between
younger and older patients for overall survival. Elderly patients
did experience more Grade 3–4 toxicity (35 vs. 18%, p< 0.001).
Based on this subgroup analysis, erlotinib seems to be a rea-
sonable option for elderly patients in the second or third line
setting (85). A trial in vulnerable elderly patients by CGA adds
further support to this opinion, since both gemcitabine followed
by erlotinib or the reverse on progression showed similar survival
and tolerability (45).
ALK TYROSINE KINASE INHIBITORS
The other actionable mutation found in NSCLC is a translocation
in echinoderm microtubule associated protein-like 4 – anaplastic
lymphoma kinase (EML4–ALK ) gene, which is found in approxi-
mately 4% of patients with adenocarcinoma (75). Data in younger
patients have been extremely promising with the use of crizotinib
for EML4–ALK translocated NSCLC (86–88). Few patients were
older than 70 years. A phase I study including 149 patients did
report a response rate of 65% (40.8–84.6%) in patients ≥65 years
(87). More recently, two other early-phase clinical trials with differ-
ent ALK TKIs demonstrated response rates >50%, with ceritinib
showing impressive responses even in crizotinib resistant disease
(89, 90). While there are little data in elderly patients, there is no
reason to believe this group would derive less benefit from ALK
TKI therapy.
CONCLUSION
An increasing proportion of patients with advanced NSCLC are
over 70 years old, raising unique challenges for treatment decision-
making. While these patients are underrepresented in clinical
trials, there is an emerging body of evidence associated with this
group. The lesson of CGA is that chronological age does not
always correlate with physiological age and a variety of impor-
tant co-morbidities and geriatric syndromes can go undetected
in a typical history and physical. Geriatric assessment provides
medical oncologists with information that can affect treatment
decision and help predict chemotherapy toxicity. Abbreviated
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CGAs or newly derived tools offer the promise of more widespread
implementation of appropriate assessment of elderly patients.
For patients fit enough to consider first line chemotherapy, a
platinum doublet appears to be a reasonable standard of care.
Adding bevacizumab does not appear to improve overall sur-
vival. In the second line, pemetrexed, docetaxel, or erlotinib are
all options for consideration. Pemetrexed would be the preferred
option for patients with non-squamous histology. For patients
with EGFR mutated disease, using an EGFR TKI as a first line
treatment is a reasonable approach, though there is little evidence
specific to elderly populations.
Further research is needed on the validation of tools that predict
chemotherapy toxicity and prognosis to facilitate informed con-
sent and treatment decisions. More studies focusing on elderly
patients are also essential to help account for the physiologic
changes inherent in this population. As we move forward, medical
oncology is becoming geriatric oncology in many ways.
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